Chronic glomerulonephritis is a progressive, irreversible disease characterized by inflammation and eventual destruction of the glomerular capillaries within the nephrons. Unlike acute forms that may resolve completely, this chronic condition develops silently over many years, slowly destroying functional renal tissue and replacing it with fibrous scar tissue. As nephrons are progressively lost, the kidneys shrink symmetrically and lose their ability to filter blood effectively, ultimately leading to end-stage renal disease (ESRD). Many patients remain completely asymptomatic during the early and middle stages, discovering the condition only during routine screening or when advanced uremic symptoms finally prompt medical evaluation.
The underlying mechanism of chronic glomerulonephritis typically involves immune-mediated injury. Circulating antigen-antibody complexes become trapped in the glomerular basement membrane, or antibodies form directly against local glomerular antigens. This immune reaction activates the complement cascade, attracting neutrophils and macrophages that release lysosomal enzymes, which damage the delicate glomerular capillaries.
Over time, this continuous inflammatory response stimulates mesangial cells to proliferate and secrete extracellular matrix proteins. The resulting glomerular sclerosis narrows the capillary lumen, reducing the glomerular filtration rate (GFR). Ischemia follows, accelerating further nephron destruction in a destructive feedback loop.
Chronic glomerulonephritis can stem from various primary renal disorders or secondary systemic diseases. Unresolved acute streptococcal glomerulonephritis is a classic historical precursor, though many cases evolve from IgA nephropathy, membranous nephropathy, or hereditary conditions like Alport syndrome. Systemic diseases frequently compromise the kidneys as well; poorly controlled systemic hypertension and diabetes mellitus are major contributors. Autoimmune disorders such as systemic lupus erythematosus also target the glomeruli over time. Identified risk factors include a family history of kidney disease, chronic exposure to certain nephrotoxic substances, and persistent systemic infections.
Medical management focuses on slowing disease progression, controlling complications, and preparing for renal replacement therapy when necessary. Antihypertensive therapy is paramount, utilizing ACE inhibitors or ARBs to reduce intraglomerular pressure and decrease proteinuria. Diuretics help manage fluid overload and peripheral edema. Dietary protein restriction is often prescribed to reduce the workload on remaining nephrons and minimize uremic toxin buildup. Phosphate binders and vitamin D supplements manage mineral and bone disorders, while erythropoiesis-stimulating agents treat renal anemia under careful blood pressure monitoring.
Nursing care centers on monitoring fluid balance, assessing nutritional status, and educating the patient and family on complex self-management regimens. Nurses must accurately track daily weights, strict intake and output, and vital signs, paying close attention to blood pressure trends. Patient education must emphasize adherence to prescribed fluid, sodium, potassium, and protein restrictions. Nurses teach patients how to recognize signs of worsening fluid overload or hyperkalemia, such as muscle weakness or palpitations, and reinforce the critical need for regular follow-up blood work.
As chronic glomerulonephritis advances inexorably, patients face severe systemic complications. Persistent hypertension frequently precipitates left ventricular hypertrophy and congestive heart failure. Severe electrolyte imbalances, particularly hyperkalemia and metabolic acidosis, threaten life. Mineral and bone disorders cause fragile bones and vascular calcification. Ultimately, the progressive loss of nephrons culminates in end-stage renal disease, requiring life-sustaining renal replacement therapy in the form of chronic dialysis or kidney transplantation for long-term survival.